Navigation Links
Molecule plays early role in nonsmoking lung cancer
Date:7/27/2009

COLUMBUS, Ohio The cause of lung cancer in never-smokers is poorly understood, but a study led by investigators at the Ohio State University Comprehensive Cancer Center and at the National Cancer Institute has identified a molecule believed to play an early and important role in its development.

The findings, published online recently in the Proceedings of the National Academy of Sciences, may lead to improved therapy for lung cancer in both never-smokers and smokers, including those with tumors resistant to targeted drugs such as gefitinib.

The study examined lung tumors from people who had never smoked and found high levels of a molecule called miR-21. The levels were even higher in tumors that had mutations in a gene called EGFR, a common feature of lung cancer in never-smokers.

"Several important lung cancer drugs target EGFR mutations, but these agents are ineffective in about 30 percent of cases in which the mutation is present," says co-principal investigator Dr. Carlo M. Croce, professor of molecular virology, immunology and medical genetics at the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute. "Our study suggests that developing agents to inhibit miR-21 might improve these anti-EGFR therapies."

About 15 percent of the 219,000 lung cancer cases expected this year in the United States 32,850 people will occur in individuals who have never smoked.

Croce and his colleagues began their study by comparing 28 cases of lung tumor tissue and nearby healthy lung tissue from never-smokers for changes in microRNA, molecules that help cells regulate the kind and amount of proteins they make.

The cancer cells showed abnormally elevated levels of five microRNAs, with miR-21 increased two and a third times, the highest of all. An earlier study of smoking-related lung cancer by the same investigators also showed elevated levels of that molecule.

Furthermore, the molecule was equally high in early stage tumors and late stage tumors, suggesting that this change happens early in lung cancer development, says Croce, who also directs Ohio State's Human Cancer Genetics program.

Using lung cancer cell lines, the investigators learned that EGFR regulates miR-21. For example, altering EGFR levels caused corresponding changes in miR-21.

Last, the investigators took cells that had a mutated EGFR gene and treated them with an anti-EGFR agent (the agent was related to gefitinib and erlotinib, targeted drugs used to treat lung cancers with EGFR mutations). As expected, many of the cells died. But when they blocked both EGFR and miR-21, the proportion of cells killed rose still more.

Overall, Croce says, "Our study suggests that the combined use of an EGFR inhibitor and a miR-21 inhibitor might improve therapy for many cases of lung cancer, and rescue lung cancer cases that have acquired resistance to several targeted drugs."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Molecule Helps Leukemia Cells Hide From Immune System
2. Small Molecule Might Play Big Part in Lung Cancer
3. New role discovered for molecule important in development of the pancreas
4. Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of Wnt Pathway
5. Ready for relapse: Molecule helps breast cancer cells to survive in the bone marrow
6. LSUHSC research identifies enzyme that makes survival molecule for key vision cells
7. Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Incs. GCS-100 Molecule
8. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
9. Molecule in Skin May Link Eczema and Asthma
10. Molecule prompts damaged heart cells to repair themselves after a heart attack
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... , ... Shark Finds and Kevin Harrington, and the Product Managers of AsSeenOnTV.pro are ... a newly patented product that has solved some of the basic problems golfers have faced ... dew or right after a rain shower, might understand the struggle of placing the club ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... BASF Human Nutrition into the Food & Beverage and Dietary ... BASF’s channel partner throughout Canada and USA geographies east of the Rocky Mountains ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... A man who has struggled to quit ... Freedom Laser Therapy , was determined to find solutions to his problems – and he ... Inventors Digest is ready to introduce his breakthrough inventions to the world and better ...
(Date:2/8/2016)... Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... and surrounding areas with a vital new community enrichment program, has teamed up with ... local women and children suffering from intimate abuse. To support all those victimized by ...
(Date:2/8/2016)... GA (PRWEB) , ... February ... ... technology and security executive networking and relationship-marketing firm, announced today that nominations ... 2016 Information Security Executive® (ISE®) West Awards. , Awards include the ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Feb. 9, 2016 The global prefilled syringes ... it is expected to grow with a CAGR of ... prefilled syringes segment dominated the global prefilled syringes market, ... --> The global market of prefilled ... to increasing geriatric population, increasing demand for vaccines, increasing ...
(Date:2/9/2016)...  Increasingly, health care professionals are enhancing patient care ... technology. With the Vios Monitoring System from Vios Medical, ... detect problems before they become serious by continuously tracking ... the United States . ... --> The Vios Monitoring System connects patient-worn ...
(Date:2/9/2016)... KONG , Feb. 9, 2016 Athenex, Inc. ... Athenex as Vice President of Corporate Strategy and Business Development ... MSc, MBA has joined as Senior Director and Deputy Head of Clinical ... . Simon Pedder stated, "Athenex has ... for a while. Coupled together with their unique business model ...
Breaking Medicine Technology: